Eisai
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eisai sits in the top decile of US sponsors by registered trial count (#121 of 15,742 sponsors by registered trial count).
Eisai: 287 sponsored US clinical trials, 5 recruiting.
Eisai sponsors 287 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 243 completed. 67 of these trials are in Phase 3-4 (later-stage) and 214 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Subjects, with 6 trials.
Top-decile sponsor footprint
Eisai ranks in the top decile of sponsors by registered trial count (#121 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
243 of 273 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
287 total, page 6 of 6
Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
NCT00760084
An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies
NCT00121732
Safety and Efficacy of APD356 in the Treatment of Obesity
NCT00116740
A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes
NCT00260065
Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
NCT01378416
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
NCT00124527
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
NCT00144690
A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma
NCT00211276
Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)
NCT00358644
Efficacy and Safety Study of E2007 in Migraine Prophylaxis
NCT00154063
Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy
NCT00100932
Safety and Efficacy of APD356 in the Treatment of Obesity
NCT00104507
Maintenance Intermittent Therapy for Symptomatic GERD Patients
NCT00165841
A Study of E7389 in Advanced/Metastatic Breast Cancer Patients
NCT00097721
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
NCT00124566
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
NCT00211185
Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients
NCT00080197
Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma
NCT00078637
The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)
NCT00293176
Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy
NCT00090376
Study of E7389 in Patients With Advanced Solid Tumors
NCT00069264
Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors
NCT00069277
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
NCT00055146
Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease
NCT00165737
Dose-Finding Study of E7070 in Combination With Irinotecan
NCT00060567
An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis
NCT01146509
A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma
NCT00059735
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
NCT00050960
Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy
NCT00056576
A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis
NCT00046072
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
NCT00211198
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
NCT00096473
Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)
NCT00051025
Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer
NCT00033735
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
NCT00051012
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
NCT00050999
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
NCT00050973
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 122 |
| Phase 2 | 92 |
| Phase 3 | 52 |
| Phase 4 | 15 |
Therapeutic Areas
What is open in the Eisai pipeline
5 recruiting of 287 indexed (2% open); 243 completed (85%).
Phase mix: 67 late (III/IV) vs 214 early (I/II) (early-phase heavy).
Top condition: Healthy Subjects (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eisai: open-pipeline peers nationwide
Peers matched on 287 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Eisai sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 287 trials (± recruiting share)
- University of Missouri-Columbia · 291 trials · 19% recruiting
- Thomas Jefferson University · 292 trials · 18% recruiting
- University of Michigan Rogel Cancer Center · 292 trials · 15% recruiting
- Kaiser Permanente · 294 trials · 7% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Medtronic Cardiac Rhythm and Heart Failure · 2% recruiting · 115 trials
- Bausch & Lomb Incorporated · 2% recruiting · 174 trials
- Lexicon Pharmaceuticals · 2% recruiting · 56 trials
- Alcon Research · 2% recruiting · 275 trials
Related
What to do with this Eisai page
287 registered trials is a research-attention snapshot, not an endorsement of Eisai or any single study.
- 5 of Eisai's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy Subjects is the condition Eisai studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Subjects trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Eisai pipeline card: 287 registered trials from official public datasets.Report a data error.